MedTrace Logo

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

NCT04076787 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1769

Last updated 2023-04-06

Study results available
· View outcomes & findings →

Summary

This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sunitinib

patients who received sunitinib as first line therapy for mRCC

Sponsors & Collaborators

  • International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)

    collaborator OTHER

  • Analysis Group, Inc.

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2018-09-02
Completion
2018-09-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04076787 on ClinicalTrials.gov